Form 4: CRL Executive Plans Future Stock Sale

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported a planned sale of 800 common shares for August 2025.

Summary

• Joseph W. LaPlume, Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International, Inc. (CRL), reported a transaction.
• The transaction involves the disposition (sale) of 800 shares of CRL common stock.
• The reported transaction date is August 18, 2025.
• The shares were sold at a price of $157.6 per share.
• Following this reported transaction, Joseph W. LaPlume will beneficially own 24,116 shares of common stock directly.

Sentiment

Score: 5

Explanation: The reported transaction is a pre-scheduled sale by an executive, occurring in the future. While an insider sale, it is likely part of a personal financial plan rather than a reaction to immediate company performance, making its sentiment impact more neutral.

Negatives

• An executive's sale of shares, even if pre-planned, can sometimes be perceived by investors as a signal of the executive's view on the stock's valuation or future prospects.

Future Outlook

The filing details a future transaction, indicating a pre-planned disposition of shares by an executive.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the executive's planned sale as a neutral to slightly negative signal, depending on their view of pre-planned insider transactions versus reactive sales.

Key Dates

Recommendation

The executive's sale of 800 shares is a pre-planned transaction for a future date, indicating it's likely part of a personal financial strategy rather than a reaction to current company performance. This type of insider activity typically has a neutral to slightly negative impact on stock sentiment, warranting a 'hold' recommendation as it doesn't suggest a fundamental shift in the company's outlook.

Keywords

Charles River Laboratories, CRL, insider trading, Form 4, stock sale, executive compensation, Joseph W. LaPlume